Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

If he had managed and assessed the company's circumstances better, he would have raised capital when he stepped in last July when the stock was at $7 rather than dragging his feet and waiting until the company had less than a year's worth of cash and he was forced to sell at an all time low price. That squarely falls on him.